First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong ELUNATE® is the first oral targeted therapy.
HUTCHMED (China) (HCM) Receives ELUNATE Marketing Approval in Hong Kong streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Hutchmed Ltd on Tuesday touted progress in Hong Kong, after its oral therapy for metastatic colorectal cancer received marketing approval in the city.
The immunotherapy developer, which was founded.
With colorectal cancer (MRC) being the second biggest cancer type in Hong Kong, it is positive news that Hutchmed has received marketing approval for its Elunate (fruquintinib) small molecule treatment.